Why Is IOVA Stock Falling Today?

Iovance Biotherapeutics (IOVA) received FDA clearance for a Phase I/II trial for its IOV-5001 therapy. The stock has surged 75.74% in 30 days and 227.78% year-to-date, but is down 66.29% over 5 years. Analysts suggest it may be 54% undervalued at $8.26, with a fair value estimate of $18.00, citing potential market expansion and revenue growth.

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

IOVA, AMLX, and COP stocks reached 52-week highs. IOVA rose 12% after strong Q2 results and analyst updates, AMLX gained over 2% on positive trial results and a $500M capital raise, and COP increased 3% following strong Q2 earnings and a price target raise. Each company saw improved investor and retail sentiment.

Iovance Biotherapeutics (IOVA) reported early clinical trial results showing lifileucel, its tumor-infiltrating lymphocyte therapy, achieved tumor responses in half of six evaluable patients with advanced soft tissue sarcomas. The company plans a registrational trial and FDA consultation for expedited review. IOVA stock rose over 5% in premarket trading. Q4 revenue was $87M, up 30% YoY, with a 50% gross margin. IOVA stock has fallen 47% over the past year.

Iovance Biotherapeutics (IOVA) surged 12% to a 52-week high after reporting Q2 revenue of $99.3M and a UBS price target raise. Amylyx Pharmaceuticals (AMLX) rose 2% on positive Phase 3 trial results and a $500M offering. ConocoPhillips (COP) gained 3% after strong Q2 earnings and a Morgan Stanley price target increase.

Iovance Biotherapeutics (IOVA) reported Q2 revenue of $99.313M, beating estimates of $87.832M. The company's stock hit a 52-week high, up over 200% year-to-date. Amtagvi, its approved therapy, drove most of the revenue. The company reaffirmed its 2026 sales guidance of $350M to $370M. Analysts adjusted price targets, with UBS raising its target to $7 and Mizuho to $11.